Search Within

Department of Medicine

Formats
  1. Journal Article (19593)
  2. Meeting Abstract (16038)
  3. Review (1150)
  4. Book Section (934)
  5. Editorial (610)
  6. Research Letter (314)
  7. Conference Paper (301)
  8. Guidelines (295)
  9. Correspondence (236)
  10. Miscellaneous (90)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22321)
  2. Hematologic Malignancies, Division of (13278)
  3. Center for Hematologic Malignancies (11061)
  4. GSK Faculty (10646)
  5. Survivorship Research (9330)
  6. Division of Subspecialty Medicine (7535)

More Groups

People
  1. Robert Motzer (1248)
  2. Howard Scher (1132)
  3. Sergio Giralt (1069)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (905)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1071)
  2. 2024 (2291)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3722)
  3. Annals of Oncology (1398)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (902)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6458)
  2. Elsevier Inc. (4216)
  3. American Society of Hematology (4003)
  4. American Association for Cancer Research (2896)
  5. Oxford University Press (2286)
  6. Nature Publishing Group (2111)

More Publishers

Results (39622)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Polygenic risk score associations with immune checkpoint inhibitors related endocrine toxicity
    Meeting Abstract

    Thorball, C. W.; Quandt, Z.; Saha, A.; Yao, L.; Midda, P.; Xu, Y.; Bejan, C. A.; Hodel, F.; Stravodimou, A.; Shearer-Kang, E.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Characteristics of real-world (RW) NATALEE and monarchE eligible populations: A US electronic health records (EHR) database analysis
    Meeting Abstract

    Tarantino, P.; Rugo, H. S.; Curigliano, G.; O'Shaughnessy, J.; Janni, W.; Jhaveri, K.; Mouabbi, J. A.; Brufsky, A. M.; Hamilton, E. P.; Oregan, R.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • HERIZON-BTC-302: A phase III study of zanidatamab with standard-of-care (SOC) therapy vs SOC alone for first-line (1L) treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced/metastatic biliary tract cancer (BTC)
    Meeting Abstract

    Macarulla Mercade, T.; Harding, J. J.; Pant, S.; Wu, X.; Garfin, P.; Okusaka, T.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Association of a blood T cell fitness gene signature with clinical benefit from ImmTAC bispecific T cell engagers
    Meeting Abstract

    Sacco, J. J.; Carvajal, R. D.; Hamid, O.; Kirk, P. B.; Collins, L.; Butler, M. O.; Shoushtari, A. N.; Hassel, J. C.; Ikeguchi, A. P.; Hernandez-Aya, L.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Updated efficacy and safety from the phase II PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC)
    Meeting Abstract

    Riely, G. J.; Ahn, M. J.; Clarke, J.; Dagogo-Jack, I.; Felip, E.; Gelsomino, F.; Goldman, J. W.; Hussein, M.; Johnson, M. L.; Morgensztern, D.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Tivozanibenivolumab vs tivozanib monotherapy in patients with renal cell carcinoma (RCC) following 1 or 2 prior therapies including an immune checkpoint inhibitor (ICI): Results of the phase III TiNivo-2 study
    Meeting Abstract

    Choueiri, T. K.; Motzer, R. J.; Beckermann, K.; Barthelemy, P.; Iacovelli, R.; Emambux, S.; Molina Cerrillo, J.; Garmezy, B.; Coelho Barata, P. M.; McKay, R. R.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Updated efficacy and safety of vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT): One-year follow-up from the MOTION phase III trial
    Meeting Abstract

    Gelderblom, H.; Bhadri, V. A.; Stacchiotti, S.; Bauer, S.; Wagner, A. J.; van de Sande, M.; Bernthal, N. M.; Lopez Pousa, A.; Abdul Razak, A. R.; Italiano, A.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • First-in-human results of STX-478, a mutant-selective PI3Ka inhibitor, in advanced solid tumor patients
    Meeting Abstract

    Montero, A. J.; Giordano, A.; Jhaveri, K.; Munster, P.; Rodon, J.; Lorusso, P.; Orr, D.; Bartolomé Arcilla, J.; Italiano, A.; Elias, A.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Final overall survival (OS) in patients (pts) with newly diagnosed advanced ovarian cancer (aOC) treated with niraparib (nir) first-line (1L) maintenance: Results from PRIMA/ENGOT-OV26/GOG-3012
    Meeting Abstract

    González-Martín, A.; Pothuri, B.; Ginesta, M. P. B.; Graybill, W. S.; Vergote, I. B.; McCormick, C.; Mirza, M. R.; Moore, R. G.; Lorusso, D.; O'Cearbhaill, R. E.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Capivasertib (C) plus paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer (mTNBC): The CAPItello-290 phase III trial
    Meeting Abstract

    Schmid, P.; McArthur, H. L.; Cortés, J.; Xu, B.; Cardoso, F.; Casalnuovo, M. L.; Demirci, U.; Freitas, R.; Ghosh, J.; Hegg, R.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save